The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity

被引:51
作者
Cuerda, C. [1 ]
Velasco, C. [1 ]
Merchan-Naranjo, J. [2 ]
Garcia-Peris, P. [1 ]
Arango, C. [2 ]
机构
[1] Univ Gregorio Maranon, Unidad Nutr, Gen Hosp, Madrid 28007, Spain
[2] Univ Gregorio Maranon, CIBERSAM, Inst Invest Sanitaria Gregorio Maranon, Dept Child & Adolescent Psychiat,Gen Hosp, Madrid 28007, Spain
关键词
food intake; physical activity; resting energy expenditure; second-generation antipsychotics; weight gain; WEIGHT-GAIN; INSULIN-RESISTANCE; METABOLIC-RATE; OLANZAPINE; SCHIZOPHRENIA; CLOZAPINE; ADOLESCENTS; RISPERIDONE; CHILDREN; DRUGS;
D O I
10.1038/ejcn.2013.253
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Second-generation antipsychotics (SGA) are associated with weight gain and metabolic alterations including hyperglycemia, dyslipidemia, hypertension and metabolic syndrome. These metabolic side effects increase cardiovascular risk and are related to medication non-compliance. Patients without previous exposure to these or other antipsychotic drugs (naive patients) seem to be more prone to develop these metabolic abnormalities. The mechanisms behind weight gain can be an increase in food intake and/or a decrease in energy expenditure. This review comprehensively examines the current knowledge on the impact of these drugs on food intake and energy expenditure. The influence of these drugs on appetite and food intake (total caloric intake and food sources) is reviewed as well as the evidence of abnormal eating behaviors. The studies evaluating the effect on resting energy expenditure are critically examined, taking into account the influence of body composition and previous exposure to antipsychotics (naive vs non-naive patients). Finally, the influence of these drugs on physical activity is also discussed. The knowledge of the mechanisms of weight gain in patients starting these drugs may be useful to further prompt research in this field and ameliorate the metabolic side effects associated with these treatments.
引用
收藏
页码:146 / 152
页数:7
相关论文
共 53 条
[1]  
Allison DB, 2001, J CLIN PSYCHIAT, V62, P22
[3]   Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004 [J].
Aparasu, Rajender R. ;
Bhatara, Vinod .
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (01) :48-55
[4]   Antipsychotic use and expenditure in the United States [J].
Aparasu, Rajender R. ;
Bhatara, Vinod .
PSYCHIATRIC SERVICES, 2006, 57 (12) :1693-1693
[5]   Adiposity and eating behaviors in patients under second generation antipsychotics [J].
Blouin, Melissa ;
Tremblay, Angelo ;
Jalbert, Marie-Eve ;
Venables, Helene ;
Bouchard, Roch-Hugo ;
Roy, Marc-Andre ;
Almeras, Natalie .
OBESITY, 2008, 16 (08) :1780-1787
[6]   Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study [J].
Bobes, Julio ;
Arango, Celso ;
Aranda, Pedro ;
Carmena, Rafael ;
Garcia-Garcia, Margarida ;
Rejas, Javier .
SCHIZOPHRENIA RESEARCH, 2007, 90 (1-3) :162-173
[7]   The unhealthy lifestyle of people with schizophrenia [J].
Brown, S ;
Birtwistle, J ;
Roe, L ;
Thompson, C .
PSYCHOLOGICAL MEDICINE, 1999, 29 (03) :697-701
[8]  
Carpenter WT, 2008, PSYCHIAT SERV, V59, P523, DOI 10.1176/ps.2008.59.5.523
[9]   The potential role of appetite in predicting weight changes during treatment with olanzapine [J].
Case, Michael ;
Treuer, Tamas ;
Karagianis, Jamie ;
Hoffmann, Vicki Poole .
BMC PSYCHIATRY, 2010, 10
[10]   Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design [J].
Coccurello, Roberto ;
Moles, Anna .
PHARMACOLOGY & THERAPEUTICS, 2010, 127 (03) :210-251